AZ HB2078

Prohibits health insurance corporations, health care services organizations, disability insurers, and group/blanket disability insurers from charging higher copayments, deductibles, or coinsurance for patient-administered cancer treatment medications (oral or self-injected) compared to provider-administered cancer treatment medications (injected or intravenous).

Applies to all policies, contracts, and evidence of coverage issued, delivered, or renewed on or after January 1, 2016.

Prevents insurers from increasing cost-sharing for provider-administered cancer medications to circumvent the equal cost-sharing requirement, but allows general increases applied across other medical or pharmaceutical benefits.

Prohibits reclassification of cancer treatment medication benefits in ways that are inconsistent with the equal cost-sharing requirements.

Defines "cancer treatment medications" as prescription drugs and biologics used to kill, slow, or prevent growth of cancerous cells.